Your session is about to expire
← Back to Search
Genotyping Intervention Supportive Care for Chemotherapy
N/A
Waitlist Available
Led By Rhonda Cooper-DeHoff, Pharm D, MS
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at pre-chemotherapy (baseline), 2 weeks, 4 weeks, and 12 weeks post initiation of chemotherapy.
Awards & highlights
Summary
This trial tests if using genetic information to guide medication choices can improve the well-being of cancer patients undergoing chemotherapy. It aims to find out if this approach reduces symptoms and side effects compared to usual care.
Eligible Conditions
- Chemotherapy
- Supportive Care
- Genotyping
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at pre-chemotherapy (baseline), 2 weeks, 4 weeks, and 12 weeks post initiation of chemotherapy.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at pre-chemotherapy (baseline), 2 weeks, 4 weeks, and 12 weeks post initiation of chemotherapy.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in patient MDASI scoring
Secondary outcome measures
Pharmaceutical Preparations
Trial Design
2Treatment groups
Active Control
Group I: Genotyping Intervention Supportive CareActive Control1 Intervention
For those randomized to the genotype intervention group, genotype results will be returned in the EHR pre-emptively and supportive care will be prescribed based on genotype results.
Group II: Delayed Genotyping Intervention Supportive CareActive Control1 Intervention
For those randomized to the delayed genotype intervention group, supportive care will be prescribed based on usual clinical practice.
Find a Location
Who is running the clinical trial?
University of FloridaLead Sponsor
1,354 Previous Clinical Trials
713,198 Total Patients Enrolled
Rhonda Cooper-DeHoff, Pharm D, MSPrincipal InvestigatorUniversity of Florida
Share this study with friends
Copy Link
Messenger